Trial Profile
Clinical experiences of switching patients from reference product Etanercept to the Biosimilar Sb4 in real life setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis; Arthritis; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
- Focus Therapeutic Use
- 05 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism